Dimensional Fund Advisors LP Trims Stock Position in Caribou Biosciences, Inc. $CRBU

Dimensional Fund Advisors LP lessened its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 33.1% in the 1st quarter, HoldingsChannel.com reports. The fund owned 673,200 shares of the company’s stock after selling 332,810 shares during the period. Dimensional Fund Advisors LP’s holdings in Caribou Biosciences were worth $1,278,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Bronte Capital Management Pty Ltd. bought a new position in Caribou Biosciences in the fourth quarter worth approximately $25,000. Creative Planning bought a new stake in Caribou Biosciences during the 2nd quarter valued at $25,000. Hudson Bay Capital Management LP bought a new stake in Caribou Biosciences during the 2nd quarter valued at $30,000. Westmount Partners LLC purchased a new stake in shares of Caribou Biosciences in the 1st quarter worth $37,000. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Caribou Biosciences by 80.0% in the 4th quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock worth $39,000 after buying an additional 10,824 shares during the period. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Trading Down 1.9%

Shares of Caribou Biosciences stock opened at $1.58 on Friday. The firm has a market capitalization of $156.70 million, a PE ratio of -1.46 and a beta of 2.38. Caribou Biosciences, Inc. has a twelve month low of $1.38 and a twelve month high of $3.54. The firm’s 50-day moving average price is $1.68 and its 200 day moving average price is $1.83.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.08. Caribou Biosciences had a negative return on equity of 84.75% and a negative net margin of 1,030.42%.The company had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.28 million. On average, sell-side analysts predict that Caribou Biosciences, Inc. will post -1.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CRBU shares. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Friday, July 17th. HC Wainwright increased their target price on shares of Caribou Biosciences from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Bank of America cut their target price on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.75.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.